Small Molecules vs. Biologics: An In-Depth Examination of the Dominant Segments and Future Drug Development Strategies in Cancer Care.
Central to the success of these combination regimens is the burgeoning role of Artificial Intelligence (AI). AI tools are being deployed across the drug development spectrum, from identifying novel synergistic targets to optimizing complex clinical trial designs and predicting which patients will best respond to a specific combination. This algorithmic approach significantly speeds up the...
0 Kommentare 0 Geteilt 790 Ansichten 0 Bewertungen